Galderma Group AG (VIE:GALD)
Austria · Delayed Price · Currency is EUR | Market Cap | 45.28B +40.6% |
| Revenue (ttm) | 5.18B +18.0% |
| Net Income | 755.38M +165.4% |
| EPS | 3.20 +166.0% |
| Shares Out | n/a |
| PE Ratio | 59.95 |
| Forward PE | 39.67 |
| Dividend | 0.38 (0.20%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | n/a |
| Open | 193.00 |
| Previous Close | 191.00 |
| Day's Range | 192.00 - 193.00 |
| 52-Week Range | 149.00 - 204.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 23, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19... [Read more]
Financial Performance
In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.
Financial numbers in USD Financial StatementsNews
Galderma Group AG Earnings Call Transcript: Q2 2026
Record H1 2026 net sales of $3.1B, up 24.6% year-on-year, with strong double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year guidance was raised to 19%-21% net sales growth, with Nemluvio on track for $1B in sales.
Galderma Group AG Earnings release: Q2 2026
Galderma Group AG released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Galderma Group AG Quarterly report: Q2 2026
Galderma Group AG has published its Q2 2026 quarterly earnings report on July 23, 2026.
Galderma Group AG Slides: Q2 2026
Galderma Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report takin...
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 b...
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC re...
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA wit...
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the ...
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differ...
Galderma Group AG Earnings Call Transcript: Q1 2026
Q1 2026 net sales rose 25.5% year-over-year to $1.473 billion, with double-digit growth across all segments and geographies. Full-year guidance for 17%-20% net sales growth and ~26% EBITDA margin is confirmed, supported by strong Dermatological Skincare and NEMLUVIO performance.
Galderma Group AG Earnings release: Q1 2026
Galderma Group AG released its Q1 2026 earnings on April 23, 2026, summarizing the period's financial results.
Galderma Group AG Slides: Q1 2026
Galderma Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the yea...
Galderma Shareholders Approve All Annual General Meeting Proposals
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at ...
Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Ala...
Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare
MIAMI--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, ...
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American A...
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollow...
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which ...
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scient...
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per sha...
Galderma Completes Successful Placement of EUR 500 Million Eurobond
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW...
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antio...
Galderma Group AG Earnings Call Transcript: Q4 2025
Record net sales and profitability were achieved, driven by innovation and strong launches across all segments. Guidance for 2026 and the midterm was raised, with Nemluvio's peak sales expectations doubled and margin expansion anticipated.